AIMS: To obtain in vivo evidence for the involvement of cytochrome P450 (CYP) 3A4 in the metabolism of brotizolam. METHODS:Fourteen healthy male volunteers received erythromycin 1200 mg day(-1) or placebo for 7 days in a double-blind randomized crossover manner. On the 6th day they received a single oral 0.5-mg dose of brotizolam, and blood samplings were performed for 24 h. RESULTS:Erythromycin treatment significantly increased the peak plasma concentration (P < 0.05), total area under the plasma concentration-time curve (P < 0.01), and elimination half-life (P < 0.01) of brotizolam. CONCLUSIONS: The present study provides in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism.
RCT Entities:
AIMS: To obtain in vivo evidence for the involvement of cytochrome P450 (CYP) 3A4 in the metabolism of brotizolam. METHODS: Fourteen healthy male volunteers received erythromycin 1200 mg day(-1) or placebo for 7 days in a double-blind randomized crossover manner. On the 6th day they received a single oral 0.5-mg dose of brotizolam, and blood samplings were performed for 24 h. RESULTS:Erythromycin treatment significantly increased the peak plasma concentration (P < 0.05), total area under the plasma concentration-time curve (P < 0.01), and elimination half-life (P < 0.01) of brotizolam. CONCLUSIONS: The present study provides in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism.
Authors: N Yasui; K Otani; S Kaneko; T Ohkubo; T Osanai; K Sugawara; K Chiba; T Ishizaki Journal: Clin Pharmacol Ther Date: 1996-05 Impact factor: 6.875
Authors: K Araki; N Yasui-Furukori; T Fukasawa; T Aoshima; A Suzuki; Y Inoue; T Tateishi; K Otani Journal: Eur J Clin Pharmacol Date: 2004-07-01 Impact factor: 2.953
Authors: N Yasui; T Kondo; K Otani; H Furukori; S Kaneko; T Ohkubo; T Nagasaki; K Sugawara Journal: Psychopharmacology (Berl) Date: 1998-10 Impact factor: 4.530
Authors: D J Greenblatt; L L von Moltke; J S Harmatz; M Counihan; J A Graf; A L Durol; P Mertzanis; S X Duan; C E Wright; R I Shader Journal: Clin Pharmacol Ther Date: 1998-09 Impact factor: 6.875
Authors: S Kondo; T Fukasawa; N Yasui-Furukori; T Aoshima; A Suzuki; Y Inoue; T Tateishi; K Otani Journal: Eur J Clin Pharmacol Date: 2005-03-18 Impact factor: 2.953
Authors: Yuanyuan Wang; Muh Akbar Bahar; Anouk M E Jansen; Janwillem W H Kocks; Jan-Willem C Alffenaar; Eelko Hak; Bob Wilffert; Sander D Borgsteede Journal: J Antimicrob Chemother Date: 2019-10-01 Impact factor: 5.790